Psychedelic Stocks Archives - Page 3 of 61

WednesdayJan 22, 2025 10:00 am

UK Study to Explore DMT’s Role in Treating Alcohol Addiction

Alcohol addiction is a chronic disorder linked to the compulsive drinking of alcohol, with individuals finding it difficult to control or stop their use of alcohol despite adverse health, occupational, or social consequences. Normally, the disorder is managed with detoxes, therapy, various medications and a change in one’s lifestyle. Now researchers are looking into whether DMT can help manage the disorder. DMT is a psychedelic drug that occurs in many plants and animals, including human beings. The drug is known to affect an individual’s senses, altering how they think as well as their emotions and sense of time. The drug…

TuesdayJan 21, 2025 10:00 am

Psilocybin Triggers Personality Changes in Individuals Suffering from AUD

Patients with alcohol use disorder frequently display unusual personality traits, characterized by increased impulsivity and lack of emotional stability, alongside lower levels of cooperativeness and self-discipline. Researchers posit that these traits fuel the addiction cycle and hinder the effectiveness of treatments. Now a new study has determined that psilocybin-assisted psychotherapy can induce positive changes in the personalities of individuals with alcohol use disorder. The researchers theorized that the personality changes triggered by psilocybin-assisted psychotherapy could help individuals recovering from alcohol dependence to endure stressors that cause relapses, given the association between impulsiveness, excessive drinking, and relapses. They also cited prior…

WednesdayJan 15, 2025 10:00 am

Native American Church Decries Shortage of Psychedelic Cactus

Peyote is a variety of cactus considered to be sacred and is used in religious rites by Native Americans. The plant only grows across northern Mexico and America’s south-western region and produces mescaline, a hallucinogenic that binds to and activates certain serotonin receptors in the brain. Last week, experts warned of a peyote shortage, labeling the psychedelic renaissance occurring in the West as one of the primary causes. The West’s psychedelic renaissance began in the 50s and 60s, as more evidence surfaced of the therapeutic benefits of psychedelics like LSD and psilocybin. This saw various personalities seek out psychedelic experiences,…

MondayJan 13, 2025 10:00 am

Psychedelics Task Force in Minnesota Asks Lawmakers to Enact Legislation to Decriminalize Psychedelics

A Minnesota Psychedelic Medicine Task Force is urging legislators to create a state-regulated program for legal therapeutic access to psychedelics and decriminalize the possession and use of low amounts of psilocybin. This government task force was established through a legislation signed by Governor Tim Walz into law in May 2024. Originally, the task force was supposed to examine ketamine, mescaline, salvinorin A, ibogaine, DMT, bufotenine, 2C-B, and 5-MeO-DMT. Following the measure’s amendment, its focus shifted to LSD, psilocybin and MDMA. Its responsibilities included advising legislators on the medical, policy, and legal issues linked to the legalization of psychedelic medicine in…

MondayJan 06, 2025 10:00 am

A Recap of the Highlights for the Psychedelics Industry in 2024

The psychedelics industry experienced various peaks and pits at both the state and federal levels in 2024. Below, we look at some of the top moments of the year. Department of Veterans Affairs to fund psychedelic research for veterans Last month, the department announced that it’d allocate $1.5 million to research the effectiveness of MDMA-assisted therapy for alcohol use disorder and post-traumatic stress disorder. This psychedelic study, the first to be funded by a federal agency since the 60s, will be conducted at West Haven VA Medical Center and Providence VA Medical Center by VA researchers affiliated with Yale University…

MondayDec 30, 2024 10:00 am

New Study Provides Insights on Links Between Ayahuasca and Improvements in Mental Health, Wellbeing

Newly-released research findings in the Psychoactive Drugs journal have brought to attention notable associations between ayahuasca use and improvements in mental health. The study leveraged data collected during an international survey that discovered that users of ayahuasca experience reduced mental distress and enjoy improved mental wellbeing. The research team observed that the positive effects above appear to be subject to several factors, such as how intense the mystical experience users underwent, the insights that individuals gained after using the substance, and the sense of belonging users felt as part of a community while using the hallucinogen. Ayahuasca has been used…

MondayDec 23, 2024 10:00 am

Study Shows Psilocybin Could Reverse Memory Loss Resulting from Stress

The active components of hallucinogenic mushrooms, psilocybin and psilocin, are known to affect the brain in different ways. For instance, they influence serotonin receptors associated with neuroplasticity, cognitive processes, and mood regulation. Prior research has demonstrated that psilocybin can increase the density of dendritic spines, stimulate genes associated with neuroplasticity, and improve synaptic plasticity. Now a new study has found that psilocybin extracts may also have a hand in reversing memory deficits brought on by chronic stress. Already, prior studies have shown that chronic stress decreases levels of brain-derived neurotrophic factor in the hippocampus, a region crucial for learning and…

WednesdayDec 18, 2024 10:00 am

Gaps While Reporting Psychotherapy Could Compromise Hallucinogenic Treatments

Psychedelics like LSD, psilocybin, ayahuasca, and MDMA have demonstrated potential in managing conditions like addiction, post-traumatic stress disorder, and depression. These drugs can give rise to profound experiences that, when paired with talk therapy, may bring about substantial therapeutic benefits. This has grown the popularity of psychedelic-assisted therapy as more and more studies tout the benefits of this approach, particularly for patients with mental health conditions who’ve gained no benefit from traditional treatments. Now new research by investigators at the University Medical Center Gröningen and the Champalimaud Foundation calls to attention gaps in how the psycho-therapeutic aspect of these therapies…

MondayDec 16, 2024 10:00 am

New Approaches to Psychedelic Clinical Trials Could Overcome Regulatory Hurdles

Lykos Therapeutics was earlier this year denied approval for their MDMA formulation developed to treat post-traumatic stress disorder. The FDA advisory panel that rejected the application cited various issues as their basis, including sexual misconduct during the clinical trials, concerns about the drug’s potential for abuse, and a failure to submit data requested. Soon after, Lykos let go of over 70% of its workforce. Following these developments, Compass Pathways PLC (NASDAQ: CMPS) recently announced that it’d be delaying its phase III trial results reporting timeline to make certain that it could endure scrutiny associated with trial blinding. Compass Pathways, which…

WednesdayDec 11, 2024 10:00 am

Psilocybin Could Improve Sleep, Mental Health

Psilocybin is a psychoactive compound that naturally occurs in some species of hallucinogenic mushrooms. When ingested, this compound is converted into psilocin and interacts with serotonin receptors in the brain. This interaction results in altered mood, perception, and cognition and may produce vivid auditory and visual experiences as well as profound spiritual and/or emotional insights. Now a new study has found that psilocybin may help improve sleep quality and reduce symptoms of depression. This isn’t the first study to investigate the therapeutic effect of psilocybin on mental health conditions either. Various studies have found that this psychedelic compound has the…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks